Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT00002246 Completed - HIV Infections Clinical Trials

A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex

Start date: October 1997
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if adding stavudine (d4T) to anti-HIV drug regimens (with or without zidovudine, ZDV) can improve symptoms of AIDS Dementia Complex (ADC, problems involving the brain or spinal cord) in HIV-positive patients.

NCT ID: NCT00002245 Completed - HIV Infections Clinical Trials

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

Start date: April 1999
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effects of a 3-drug anti-HIV regimen, amprenavir (APV) plus abacavir (ABC) plus lamivudine (3TC), on the way carbohydrates (sugars) and fats are metabolized (processed by the body) in HIV-infected patients who have received little or no previous anti-HIV drug therapy.

NCT ID: NCT00002244 Completed - HIV Infections Clinical Trials

A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if it is safe and effective to give WF10 to adults with late-stage HIV disease. WF10 is suspected to help the immune system fight infection and slow HIV disease progression.

NCT ID: NCT00002243 Completed - HIV Infections Clinical Trials

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of a new non-nucleoside reverse transcriptase inhibitor (NNRTI), (+)-calanolide A, in HIV-positive patients who have never received anti-HIV treatment.

NCT ID: NCT00002240 Completed - HIV Infections Clinical Trials

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

Start date: March 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine). The effectiveness of BMS-232632 against HIV infection will be compared to that of nelfinavir, a protease inhibitor that is already commonly prescribed.

NCT ID: NCT00002239 Completed - HIV Infections Clinical Trials

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

Start date: May 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs. The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV). Three different doses of T-20 are tested.

NCT ID: NCT00002238 Completed - HIV Infections Clinical Trials

Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

Start date: n/a
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of interferon beta (Betaseron) in AIDS and advanced AIDS related complex (ARC) patients receiving a reduced-dose zidovudine (AZT) regimen.

NCT ID: NCT00002237 Completed - HIV Infections Clinical Trials

A Study of Peldesine (BCX-34) in HIV-Infected Patients

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.

NCT ID: NCT00002236 Completed - HIV Infections Clinical Trials

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.

NCT ID: NCT00002235 Completed - HIV Infections Clinical Trials

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

Start date: n/a
Phase: Phase 2
Study type: Interventional

Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).